Review

pe conjugated vegfa (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems pe conjugated vegfa

Fig. 6. Endothelial PFKFB3 inhibition with PA compounds act on the <t>VEGFA/VEGFR2</t> axis in basal and inflammatory conditions. qRT-PCR analysis revealing downregulation of angiogenic genes (a) VEGFR2, (b) VEGFA and (c) TGF-β expression in EHECs treated with PA-1 and PA-2. (d) Relative protein expression of VEGFR2 in EHECs showing reduction upon treatment with PA-1 and PA-2. (e) By flow cytometry, a marked reduction of intracellular VEGFA production was observed in HUVECs treated with PA-1. Representative histograms show reduced VEGFA–positive ECs by PA-1 (orange) as compared to control (grey). No change was observed in HUVECs treated with PA-2 (green). (f) Heatmap indicating fold changes in expression levels of genes related to glycolysis, migration, and angio genesis upon treatment with PA-1 and PA-1 together with TNF-α in EHECs (left) and HUVEC (right). Green color represents downregulation of mRNA levels. Treatment EHEC: 20 µM 3PO, PA-1 and PA-2. Treatment HUVEC: 20 µM 3PO and PA-2, 5 µM PA-1. All experiments were performed at least three times. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.

Pe Conjugated Vegfa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pe+conjugated+vegfa/Human+VEGF+PE-conjugated+Antibody/pm33813027-250-6-9
Average 92 stars, based on 9 article reviews

pe conjugated vegfa - by Bioz Stars, 2026-10

92/100 stars

Images

1) Product Images from "In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3."

Article Title: In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3.

Journal: Pharmacological research

doi: 10.1016/j.phrs.2021.105592

Fig. 6. Endothelial PFKFB3 inhibition with PA compounds act on the VEGFA/VEGFR2 axis in basal and inflammatory conditions. qRT-PCR analysis revealing downregulation of angiogenic genes (a) VEGFR2, (b) VEGFA and (c) TGF-β expression in EHECs treated with PA-1 and PA-2. (d) Relative protein expression of VEGFR2 in EHECs showing reduction upon treatment with PA-1 and PA-2. (e) By flow cytometry, a marked reduction of intracellular VEGFA production was observed in HUVECs treated with PA-1. Representative histograms show reduced VEGFA–positive ECs by PA-1 (orange) as compared to control (grey). No change was observed in HUVECs treated with PA-2 (green). (f) Heatmap indicating fold changes in expression levels of genes related to glycolysis, migration, and angio genesis upon treatment with PA-1 and PA-1 together with TNF-α in EHECs (left) and HUVEC (right). Green color represents downregulation of mRNA levels. Treatment EHEC: 20 µM 3PO, PA-1 and PA-2. Treatment HUVEC: 20 µM 3PO and PA-2, 5 µM PA-1. All experiments were performed at least three times. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.

Figure Legend Snippet: Fig. 6. Endothelial PFKFB3 inhibition with PA compounds act on the VEGFA/VEGFR2 axis in basal and inflammatory conditions. qRT-PCR analysis revealing downregulation of angiogenic genes (a) VEGFR2, (b) VEGFA and (c) TGF-β expression in EHECs treated with PA-1 and PA-2. (d) Relative protein expression of VEGFR2 in EHECs showing reduction upon treatment with PA-1 and PA-2. (e) By flow cytometry, a marked reduction of intracellular VEGFA production was observed in HUVECs treated with PA-1. Representative histograms show reduced VEGFA–positive ECs by PA-1 (orange) as compared to control (grey). No change was observed in HUVECs treated with PA-2 (green). (f) Heatmap indicating fold changes in expression levels of genes related to glycolysis, migration, and angio genesis upon treatment with PA-1 and PA-1 together with TNF-α in EHECs (left) and HUVEC (right). Green color represents downregulation of mRNA levels. Treatment EHEC: 20 µM 3PO, PA-1 and PA-2. Treatment HUVEC: 20 µM 3PO and PA-2, 5 µM PA-1. All experiments were performed at least three times. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.

Techniques Used: Inhibition, Quantitative RT-PCR, Expressing, Flow Cytometry, Control, Migration

Staining:

Article Title: In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3.
Article Snippet: HUVECs were treated with the three compounds, 3PO, PA-1 and PA2 in culture EBM-medium for 24 h. Where after cells were detached, and cells were fixed, and permeabilized with CytoFix/Cytoperm kit (BD Biosciences) accordingly to manufacturer. .. Cells were washed and stained with PE-conjugated VEGFa (IC2931P, R&D Systems) for 30 min at 4 ◦C. .. Fluorescence intensity was measured using a BD FACSCanto II flow cytometer.

Image Search Results

Journal: Pharmacological research

Article Title: In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3.

doi: 10.1016/j.phrs.2021.105592

Figure Lengend Snippet: Fig. 6. Endothelial PFKFB3 inhibition with PA compounds act on the VEGFA/VEGFR2 axis in basal and inflammatory conditions. qRT-PCR analysis revealing downregulation of angiogenic genes (a) VEGFR2, (b) VEGFA and (c) TGF-β expression in EHECs treated with PA-1 and PA-2. (d) Relative protein expression of VEGFR2 in EHECs showing reduction upon treatment with PA-1 and PA-2. (e) By flow cytometry, a marked reduction of intracellular VEGFA production was observed in HUVECs treated with PA-1. Representative histograms show reduced VEGFA–positive ECs by PA-1 (orange) as compared to control (grey). No change was observed in HUVECs treated with PA-2 (green). (f) Heatmap indicating fold changes in expression levels of genes related to glycolysis, migration, and angio genesis upon treatment with PA-1 and PA-1 together with TNF-α in EHECs (left) and HUVEC (right). Green color represents downregulation of mRNA levels. Treatment EHEC: 20 µM 3PO, PA-1 and PA-2. Treatment HUVEC: 20 µM 3PO and PA-2, 5 µM PA-1. All experiments were performed at least three times. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Cells were washed and stained with PE-conjugated VEGFa (IC2931P, R&D Systems) for 30 min at 4 ◦C.

Techniques: Inhibition, Quantitative RT-PCR, Expressing, Flow Cytometry, Control, Migration

Significance of changes in RNA and protein expression between initial diagnosis and recurrence

Journal: Oncotarget

Article Title: Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway

doi:

Figure Lengend Snippet: Significance of changes in RNA and protein expression between initial diagnosis and recurrence

Article Snippet: Slides immunostained for VEGFA (Goat IgG, R&D Systems, Lille, France, Europe), VEGFR1 (Goat IgG, R&D Systems, Europe), VEGFR2 (clone SSB11, Rabbit IgG, Cell Signalling), CXCL12 (clone C-19, Goat IgG, Santa Cruz, Biotechnology Inc, Heidelberg, Germany) and CXCR4 (clone 44716, Mouse IgG2B, R&D Systems, Europe) were scored by a pathologist (DFB).

Techniques: Expressing, Biomarker Discovery

Prognostic value of initial and recurrent factors for progresson-free survival (PFS) and overall survival (OS) at initial diagnosis and recurrence